Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;86(6):942-952.
doi: 10.1111/his.15401. Epub 2024 Dec 20.

CD23 expression in lymphoplasmacytic lymphoma: Clinical-pathological and biological correlations

Marco Pizzi  1 , Nicolò Danesin  2 , Federico Scarmozzino  1 , Martina Pinto  1 , Greta Scapinello  2 , Luisa Santoro  1 , Irene Bertozzi  3 , Gaetano Paride Arcidiacono  3 , Valentina Trimarco  2 , Andrea Visentin  2 , Livio Trentin  2 , Francesco Piazza  2 , Angelo Paolo Dei Tos  1
Affiliations

CD23 expression in lymphoplasmacytic lymphoma: Clinical-pathological and biological correlations

Marco Pizzi et al. Histopathology. 2025 May.

Abstract

Aims: The diagnosis of lymphoplasmacytic lymphoma (LPL) in the bone marrow (BM) is challenged by aberrant phenotypes and by overlapping histological features with marginal zone lymphoma (MZL). To address these issues, we (i) assessed LPL immunophenotype on a large series of BM samples, (ii) drew possible correlations between LPL phenotype and clinical/molecular data and (iii) investigated the role of new phenotypical markers in the differential diagnosis between LPL and MZL.

Materials and methods: The study retrospectively considered 81 clinically annotated LPL diagnosed at Padua University Hospital (Padua, Italy) during a 5-year period. BM findings were correlated with clinical laboratory findings and with MYD88 and CXCR4 mutational status. The obtained results were compared with a series of 77 MZL in the BM, including 46 splenic MZL (SMZL), 14 nodal MZL (NMZL) and 17 extra-nodal MZL (EMZL).

Results: The LPL cohort included 52 males and 29 females (median age at diagnosis = 71 years). Aberrant CD10 and CD5 positivity was documented in 3 of 81 (3.7%) and 13 of 81 (16.1%) cases, respectively. CD23 positivity occurred in 56 of 81 (69.1%) cases, being usually partial/focal. CD23 expression did not correlate with any specific clinical-pathological parameter. Comparison with SMZL, NMZL and EMZL highlighted less frequent splenomegaly, higher serum paraprotein, higher CD23 expression and fewer follicular dendritic cell networks in LPL. A combined clinical-pathological score supported the differential diagnosis between LPL and MZL of any type. The highest diagnostic yield was obtained for the differential diagnosis between LPL and SMZL.

Conclusions: Partial positivity for CD23 is a common feature of LPL in the BM. Together with other clinical and histological parameters, CD23 expression supports the differential diagnosis between LPL and MZL.

Keywords: CD23; immunophenotype; lymphoma biology; lymphoplasmacytic lymphoma; marginal zone lymphoma.

PubMed Disclaimer

References

    1. McMaster ML. The epidemiology of Waldenström macroglobulinemia. Semin. Hematol. 2023;60:65–72. https://doi.org/10.1053/j.seminhematol.2023.03.008.
    1. Treon SP, Tedeschi A, San‐Miguel J, Garcia‐Sanz R, Anderson KC, Kimby E, Minnema MC, Benevolo G, Qiu L, Yi S, Terpos E, Tam CS, Castillo JJ, Morel P, Dimopoulos M, Owen RG Report of consensus panel 4 from the 11th international workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. Semin. Hematol. 2023 Mar;60:97–106. https://doi.org/10.1053/j.seminhematol.2023.03.009.
    1. Dimopoulos MA, Anagnostopoulos A. et al. Waldenström's macroglobulinemia. Best Pract. Res. Clin. Haematol. 2005;18:747–765. https://doi.org/10.1016/j.beha.2005.01.028.
    1. Askari E, Rodriguez S, Garcia‐Sanz R. et al. Waldenström's macroglobulinemia: An exploration into the pathology and diagnosis of a complex B‐cell malignancy. J Blood Med. 2021 30:795–807. https://doi.org/10.2147/JBM.S267938.
    1. Dogliotti I, Jiménez C, Varettoni M., Talaulikar D., Bagratuni T., Ferrante M., Pérez J., Drandi D., Puig N., Gilestro M., García‐Álvarez M., Owen R., Jurczak W., Tedeschi A., Leblond V., Kastritis E., Kersten M.J., D'Sa S., Kaščák M., Willenbacher W., Roccaro A.M., Poulain S., Morel P., Kyriakou C., Fend F., Vos J.M.I., Dimopoulos M.A., Buske C., Ferrero S., García‐Sanz R. Diagnostics in Waldenström's macroglobulinemia: A consensus statement of the European consortium for Waldenström's macroglobulinemia. Leukemia 2023;37:388–395. https://doi.org/10.1038/s41375‐022‐01762‐3.

LinkOut - more resources